(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2009 (14.05.2009)

PCT

(10) International Publication Number
WO 2009/061713 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 9/20* (2006.01)
A61K 31/216 (2006.01)

(21) International Application Number:
PCT/US2008/082324

(22) International Filing Date:
4 November 2008 (04.11.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/985,668 6 November 2007 (06.11.2007) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AL-FAYOUMI, Suliman** [JO/US]; 31 Knollwood Drive, Morristown, NJ 07960 (US). **HU, Jiahui** [CN/US]; 92 Bradley Lane, Bridgewater, NJ 08807 (US). **KUMARAPERUMAL, Natrajan** [IN/US]; 40-B, Byrne Court, Wayne, NJ 07470 (US). **ROYCE, Alan, Edward** [US/US]; RR 4 Box 9LE, Saylorsburg, PA 18353 (US). **RUEGGER, Colleen** [US/US]; 89 Poplar Drive, Morris Plains, NJ 07950 (US). **ZANNOU, Erika, Aina** [FR/US]; 12 Mary Ellen Drive, Edison, NJ 08820 (US).

(74) Agent: **MAJKA, Joseph, T.**; Novartis, Patent Department, One Health Plaza, Bldg. 101 - 2nd Floor, East Hanover, NJ 07936-1080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

WO 2009/061713 A1

(54) Title: DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR

(57) Abstract: Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate]hemipentahydrate.